| Status | Suspended |
| Decision | Selected |
| Process | STA pre-2018 |
| Referral date | 01 June 2010 |
| Topic area |
|
| Description |
Scoped within Batch 10 NICE has been informed by the manufacturer, AstraZeneca, that they have withdrawn their licensing application for the above indication. Therefore this topic has been suspended and the committee discussion that was due to take place on 24 March 2011 has been cancelled. We will continue to monitor any development and update this webpage if the situation changes. |
Provisional Schedule
| Closing date for invited submissions / evidence submission: | 9 December 2010 |
| 1st appraisal committee meeting: | TBC |
Project Team
| Communications manager: | Alice Law |
| Executive Lead: | Andrew Dillon |
| Project manager: | Liz Walker |
| Technical Lead: | Raisa Sidhu |
Stakeholders
| Manufacturers/sponsors | AstraZeneca (quetiapine) |
| Others | Department of Health |
| Welsh Assembly Government | |
| Patient/carer groups | Anxiety UK |
| Professional groups | British Association for Psychopharmacology |
| Royal College of Nursing | |
| Royal College of Pathologists | |
| Associated guideline groups | None |
| Associated public health groups | None |
| Comparator manufacturers | Dr Reddy's Laboratories (fluoxetine, sertraline) |
| Eli Lilly (duloxetine, fluoxetine) | |
| Pfizer (pregabalin, venlafaxine, sertraline, mirtazapine, paroxetine) | |
| Evidence review group | National Institute for Health Research Health Technology Assessment Programme |
| School of Health & Related Research Sheffield (ScHARR) | |
| General | British National Formulary |
| Care Quality Commission | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Relevant research groups | None |
For further information on our processes and methods, please see our CHTE processes and methods manual